All News

Rising rates of obesity and diabetes have raised concerns that more people could be headed for end-stage renal disease (ESRD); thus, Medicare has been seeking ways to reduce the cost of care and to improve the quality of life for people on dialysis. Scientists are focusing on whether more patients with early-stage type 2 diabetes should take sodium glucose co-transporter 2 inhibitors, which have been shown to slow renal decline.

A report released this week by the Kaiser Family Foundation illustrates how immigration policy changes at the federal level are affecting an increasing number of families, some of whom are disenrolling themselves and their children from California’s Medicaid program and not renewing or not enrolling in other programs, even though they are eligible and not directly affected by the policy changes. Experts are worried about long-term health effects.

The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease. The drug, approved under the 505(b)(2) regulatory pathway on the basis of its bioequivalence to dimethyl fumarate (Tecfidera), will be sold as Vumerity.

The number of uninsured children in the United States rose by more than 400,000 between 2016 and 2018 and now stands at over 4 million; mortality from heart failure rose 20.7% between 2011 and 2017 and is likely to keep climbing sharply; US District Judge Myron Thompson issued a preliminary injunction temporarily blocking Alabama from enforcing a near-total abortion ban.

Access and quality are inseparable, so providers prioritizing population health goals can find success by starting from a solid foundation of patient access. So how can providers streamline access to care and directly influence population health? The answer lies with sophisticated patient engagement technology.

The National Institutes of Health (NIH) has announced plans to invest at least $100 million over the next 4 years to develop gene-based therapies for 2 diseases: HIV and sickle cell disease. The Bill and Melinda Gates Foundation will also contribute $100 million to the goal of advancing these potential cures, with an aim toward providing affordable, globally available treatment that will be accessible to patients in low-resource settings.

In 2017, an estimated 5.5 million Americans were diagnosed with Alzheimer disease (AD) and 200,000 under 65 years of age are described as having early-onset AD. Even more striking is the finding that 47 million Americans are presymptomatic with stage I AD. These dire statistics beg the question about the merits of getting tested for AD since lifestyle changes can help people at risk, but they are less likely to improve the conditions of those already experiencing cognitive impairment or dementia.

Unlike many other cancer rates that have been on the decline, liver cancer rates for new liver and intrahepatic bile duct cancer cases have been rising. This October, which is Liver Cancer Awareness Month, Global Liver Institute is joining with more than 30 other leading health and medical organizations, to issue a global call-to-action to increase the 5-year survival rates for patients with liver cancer from 18% to 36% by 2030.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo